Btk Inhibition: the Importance of Being Selective
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Thomas J, Sideras P, Smith C, Vorechovsky I, Chapman V, Paul W
. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 1993; 261(5119):355-8.
DOI: 10.1126/science.8332900.
View
2.
Wang M, Rule S, Martin P, Goy A, Auer R, Kahl B
. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-16.
PMC: 4513941.
DOI: 10.1056/NEJMoa1306220.
View
3.
Kuter D, Efraim M, Mayer J, Trneny M, McDonald V, Bird R
. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022; 386(15):1421-1431.
DOI: 10.1056/NEJMoa2110297.
View
4.
Rayes J, Watson S, Nieswandt B
. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest. 2019; 129(1):12-23.
PMC: 6307936.
DOI: 10.1172/JCI122955.
View
5.
Bye A, Unsworth A, Desborough M, Hildyard C, Appleby N, Bruce D
. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2018; 1(26):2610-2623.
PMC: 5728643.
DOI: 10.1182/bloodadvances.2017011999.
View